Key result
Low plasma corin concentrations were an independent predictor of major adverse cardiac events in >1,300 patients with acute myocardial infarction over a median follow-up of 634 days.
Why the study?
Does plasma corin concentration predict major adverse cardiac events in patients with acute myocardial infarction?
Does plasma corin concentration predict major adverse cardiac events in patients with acute myocardial infarction?
Plasma corin is a novel biomarker that provides incremental prognostic value for risk stratification in patients with acute myocardial infarction.
The study by Zhou et al . recently published in the J Am Coll Cardiol provides new insights into the prognostic utility of the novel biomarker corin for risk stratification of patients with acute myocardial infarction (AMI) (1). In this prospective cohort study comprising more than 1,300 patients with ST-elevation myocardial infarction (STEMI) and non-STEMI (NSTEMI), low plasma corin concentrations were an independent predictor of major adverse cardiac events (MACE) defined as a composite endpoint of all-cause mortality, hospitalization for heart failure or recurrent AMI at a median follow-up duration of 634 days. This study impressively pointed out the incremental prognostic value of plasma corin concentrations in AMI patients beyond clinical characteristics and traditional cardiac biomarkers.
No takes yet. Share an insight, caveat, or question.
Feistritzer et al. (2016) conducted an editorial in Acute myocardial infarction (AMI) (n=1,300). Low plasma corin concentrations was evaluated on Major adverse cardiac events (MACE) defined as a composite of all-cause mortality, hospitalization for heart failure or recurrent AMI. Low plasma corin concentrations were an independent predictor of major adverse cardiac events in >1,300 patients with acute myocardial infarction over a median follow-up of 634 days.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: